Forecasting PARP Inhibitor Resistance in Breast Cancer Patients

Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Anant Madabhushi, PhD, and Farzad Fereidouni, PhD, are developing the MarginCall technology to reduce time lag and improve tumor margin assessment accuracy in breast and ovarian cancer surgery.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Tucatinib plus trastuzumab was well tolerated in patients with metastatic breast cancer and consistent with the combination’s established safety profile.

The phase 3 INAVO120 trial reported statistically significant OS results in patients with PIK3CA-mutant, locally advanced or metastatic breast cancer.